Blood Purification
Original Paper
Effects of Crit-Line® Monitor Use on Patient Outcomes and Epoetin Alfa Dosing following Onset of Hemodialysis: A Propensity Score-Matched StudySibbel S.P.a · Ficociello L.H.b · Black M.b · Thakuria M.b · Mullon C.b · Diaz-Buxo J.b · Alfieri T.J.aaDaVita Clinical Research, Minneapolis, Minn., and bFresenius Medical Care North America, Waltham, Mass., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: October 18, 2013
Accepted: March 06, 2014
Published online: June 26, 2014
Issue release date: July 2014
Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 3
ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)
For additional information: https://www.karger.com/BPU
Abstract
Background: The Crit-Line® monitor (CLM) is a device for monitoring hematocrit, oxygen saturation and change in intravascular blood volume during hemodialysis. Prior studies have evaluated CLM use in dialysis patients, but not specifically in those new to dialysis. Methods: In this retrospective analysis, 199 patients initiating dialysis at 8 facilities routinely using CLM were compared with 796 propensity score-matched non-CLM patients initiating dialysis at facilities not using CLM. Outcomes were considered over the first 180 days on dialysis. Results: Overall, the CLM group had higher StdKt/V (p = 0.06) and received lower doses of intravenous iron than the non-CLM group (p < 0.001). Erythropoiesis-stimulating agent doses were lower in the CLM group in months 1-5. Serum iron and transferrin saturation levels were higher overall for the CLM group than the non-CLM group (p = 0.004 and 0.01, respectively). Hemoglobin levels and time to first hospitalization were similar for both groups. Conclusion: Use of CLM is associated with lower erythropoiesis-stimulating agent and iron use in incident hemodialysis patients.
© 2014 S. Karger AG, Basel
Related Articles:
References
-
The United States Renal Data System 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, 2013.
- Voroneanu L, Cusai C, Hogas S, Ardeleanu S, Onofriescu M, Nistor I, Prisada O, Sascau R, Goldsmith D, Covic A: The relationship between chronic volume overload and elevated blood pressure in hemodialysis patients: use of bioimpedance provides a different perspective from echocardiography and biomarker methodologies. Int Urol Nephrol 2010;42:789-797.
- Agarwal R: Hypervolemia is associated with increased mortality among hemodialysis patients. Hypertension 2010;56:512-517.
- Chazot C, Vo-Van C, Zaoui E, Vanel T, Hurot JM, Lorriaux C, Mayor B, Deleaval P, Jean G: Fluid overload correction and cardiac history influence brain natriuretic peptide evolution in incident haemodialysis patients. Nephrol Dial Transplant 2011;26:2630-2634.
- Agarwal R, Alborzi P, Satyan S, Light RP: Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009;53:500-507.
- Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, Malecka-Masalska T, Marcelli D: The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009;24:1574-1579.
- Flythe JE, Kimmel SE, Brunelli SM: Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 2011;79:250-257.
- Movilli E, Gaggia P, Zubani R, Camerini C, Vizzardi V, Parrinello G, Savoldi S, Fischer MS, Londrino F, Cancarini G: Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 2007;22:3547-3552.
- Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK: Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006;69:1222-1228.
- Shoji T, Tsubakihara Y, Fujii M, Imai E: Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004;66:1212-1220.
- Rodriguez HJ, Domenici R, Diroll A, Goykhman I: Assessment of dry weight by monitoring changes in blood volume during hemodialysis using Crit-Line. Kidney Int 2005;68:854-861.
- Sinha AD: Why assistive technology is needed for probing of dry weight. Blood Purif 2011;31:197-202.
- Sinha AD, Light RP, Agarwal R: Relative plasma volume monitoring during hemodialysis aids the assessment of dry weight. Hypertension 2010;55:305-311.
- Wabel P, Chamney P, Moissl U, Jirka T: Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Blood Purif 2009;27:75-80.
- Leypoldt JK, Cheung AK, Steuer RR, Harris DH, Conis JM: Determination of circulating blood volume by continuously monitoring hematocrit during hemodialysis. J Am Soc Nephrol 1995;6:214-219.
- Reddan DN, Szczech LA, Hasselblad V, Lowrie EG, Lindsay RM, Himmelfarb J, Toto RD, Stivelman J, Winchester JF, Zillman LA, Califf RM, Owen WF Jr: Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol 2005;16:2162-2169.
-
Guo S, Fraser MW: Propensity Score Analysis: Statistical Methods and Applications. Thousand Oaks, Sage Publications, 2010.
- Schroeder KL, Sallustio JE, Ross EA: Continuous haematocrit monitoring during intradialytic hypotension: precipitous decline in plasma refill rates. Nephrol Dial Transplant 2004;19:652-656.
- Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW: Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 2011;6:1326-1332.
- McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK, Burton JO, Hothi D, Korsheed S, Owen PJ, Lai KB, Li PK: Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:133-141.
- Reyes-Bahamonde J, Raimann JG, Thijssen S, Levin NW, Kotanko P: Fluid overload and inflammation - a vicious cycle. Semin Dial 2013;26:31-35.
- Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003;42:761-773.
- Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S, De Simone W, Mandalari A, Brunori G, Amato M, Cianciaruso B, Zoccali C: Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006;21:991-998.
-
Centers for Medicare & Medicaid Services: End-Stage Renal Disease Prospective Payment System and Quality Incentive Program. Final Rule Fed Regist 2013;78:72156-72251.
- Parker TF 3rd, Hakim R, Nissenson AR, Krishnan M, Bond TC, Chan K, Maddux FW, Glassock R: A quality initiative. Reducing rates of hospitalizations by objectively monitoring volume removal. Nephrol News Issues 2013;27:30-32, 34-36.
Article / Publication Details
Received: October 18, 2013
Accepted: March 06, 2014
Published online: June 26, 2014
Issue release date: July 2014
Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 3
ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)
For additional information: https://www.karger.com/BPU
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
